{"id":"W3038487399","doi":"10.1158/1078-0432.ccr-20-0219","title":"A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i> -mutant Ovarian Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"Merck; AstraZeneca","keywords":"Carboplatin; Medicine; Tolerability; Internal medicine; Chemotherapy; Oncology; Adverse effect; Ovarian cancer; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Placebo; Clinical endpoint; Hazard ratio; Pemetrexed; Cancer; Progression-free survival; Randomized controlled trial; Surgery; Phases of clinical research; Confidence interval; Cisplatin; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001229659,0.001318234,0.001912083,0.0003579994,0.0004095368,0.0008048789,0.0006414717,0.001245204,0.00441677],"category_scores_gemma":[0.001011262,0.0006049901,0.00107719,0.0003807048,0.0007902695,0.0006659282,0.0003250141,0.001855142,0.0007917635],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007969483,"about_ca_system_score_gemma":0.001599892,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007903738,"about_ca_topic_score_gemma":0.002302877,"domain_scores_codex":[0.9995375,0.0002612289,0.00002744044,0.00008366066,0.00003229149,0.00005800545],"domain_scores_gemma":[0.9994881,0.0001039352,0.0001137549,0.00003563934,0.00003594641,0.0002225376],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.969234,0.009146723,0.001432166,0.0002666083,0.0006252484,0.00003415559,0.0000384896,0.0003050049,0.004636846,0.00008217273,0.0006989067,0.01349978],"study_design_scores_gemma":[0.9217281,0.07429216,0.002300483,0.00001193066,0.0002346375,0.00002954928,0.00001366364,0.0002691397,0.0004320699,0.00009345856,0.0005864724,0.000008412665],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898692,0.00215348,0.0003630694,0.0005688586,0.0003094136,0.004266289,0.000996545,0.00005714893,0.001415984],"genre_scores_gemma":[0.9871114,0.001200503,0.001460584,0.001317283,0.0003046054,0.004546914,0.001729695,0.0000128468,0.00231621],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00441677,"threshold_uncertainty_score":0.01477557,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2055678216368092,"score_gpt":0.4904681500289786,"score_spread":0.2849003283921694,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}